Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JATT III Acquisition Corp was a special purpose acquisition company (SPAC), also known as a blank check company, formed to target the life sciences and biotechnology sectors. It was the third such vehicle organized by the management team behind JATT Acquisition Corp, which successfully merged with Zura Bio. Although the company filed for an initial public offering (IPO) to raise capital for a future merger, it ultimately withdrew its registration statement in late 2023 amid a challenging market for SPACs. Consequently, the entity did not complete a business combination or commence active operations in the healthcare sector. The company was led by experienced healthcare executives and investors who sought to provide a public market platform for innovative therapeutic companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JATT III Acquisition Corp.